| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043257094 |
| P356 | DOI | 10.1038/SJ.LEU.2404333 |
| P698 | PubMed publication ID | 16888617 |
| P5875 | ResearchGate publication ID | 6897457 |
| P2093 | author name string | W I Bensinger | |
| P2860 | cites work | Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma | Q33348936 |
| Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect | Q34487436 | ||
| Drug insight: thalidomide as a treatment for multiple myeloma | Q36304004 | ||
| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects | Q40706569 | ||
| Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. | Q43488186 | ||
| Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma | Q43632773 | ||
| Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma | Q44071975 | ||
| Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome | Q44083618 | ||
| Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality | Q44189564 | ||
| 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies | Q44201995 | ||
| Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation | Q44386867 | ||
| Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning | Q44418467 | ||
| 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials | Q44429171 | ||
| Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation | Q44888557 | ||
| Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. | Q45005783 | ||
| Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. | Q45076113 | ||
| A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma | Q45138883 | ||
| Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen | Q46368527 | ||
| Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma | Q46509828 | ||
| Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma | Q46720756 | ||
| Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 | ||
| Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. | Q54657115 | ||
| Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres | Q57904065 | ||
| Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity | Q61651657 | ||
| Graft-versus-myeloma effect in two cases | Q71060552 | ||
| Graft-versus-myeloma effect | Q71264400 | ||
| Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect | Q73014175 | ||
| Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation | Q73072066 | ||
| Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation | Q73117300 | ||
| Donor leukocyte infusions for multiple myeloma | Q73375198 | ||
| Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers | Q73427004 | ||
| Mixed hematopoietic chimerism after hematopoietic stem cell allografts | Q74616585 | ||
| Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation | Q74823803 | ||
| Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation | Q76381510 | ||
| Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma | Q77227215 | ||
| Graft-versus-myeloma | Q77597294 | ||
| Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning | Q78834266 | ||
| Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma | Q79362735 | ||
| Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma | Q82192536 | ||
| Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma | Q83101491 | ||
| Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | Q83300465 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 1683-1689 | |
| P577 | publication date | 2006-08-03 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma | |
| P478 | volume | 20 |
| Q41480472 | CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy |
| Q37447307 | Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia |
| Q37832506 | Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation |
| Q36805875 | Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy |
| Q37189281 | Modern treatment options for elderly patients with multiple myeloma |
| Q80764931 | Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma |
| Q44113778 | Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors |
| Q33507242 | Thymocyte expansion and maturation: crosstalk of CD44v6 on thymocytes and panCD44 on stroma cells |
| Q37284081 | Treatment of myeloma: cure vs control |
Search more.